[Macular thickness might be a recurrence probability predictor in macular edema due to retinal vein occlusions treated with repeated intravitreal injections of antiangiogenics].
Gallego-Pinazo
R
R
Díaz-Llopis
M
M
Francés
E
E
López-Lizcano
R
R
Gómez-Maestra
M
M
Udaondo
P
P
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000209:etiology / Q000473:pathology*; D011379:Prognosis; D000069579:Ranibizumab; D012008:Recurrence; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000069579:Ranibizumab